Prof. Xavier Montalban - What’s New in Relapsing MS? Expert Perspectives on Pathogenesis, Targeting B Cells for Treatment, and Advances in Disease-State Monitoring - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:14.106950
Go online to PeerView.com/NXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances—in understanding of disease pathogenesis, emerging therapies, and new imaging approaches—have the potential to significantly improve care of individuals with multiple sclerosis (MS). The recognition of a central role for B lymphocytes in MS pathogenesis and development of two classes of therapeutic agents that target B cells—anti-CD20 antibodies and Bruton tyrosine kinase (BTK) inhibitors—facilitates the use of more novel disease-modifying therapies (DMTs). In addition, advances in imaging approaches can enhance diagnosis, disease monitoring, and treatment guidance. In this activity, based on a recent live webcast, our expert faculty will offer insight into the pathogenesis of MS, targeting B cells for the treatment of MS, and novel imaging approaches for monitoring disease status and treatment in relapsing MS. Upon completion of this activity, participants should be better able to: Summarize current perspectives on the roles of diverse cell types (eg, B and T lymphocytes, microglia, astrocytes) in the pathogenesis of relapsing MS, Apply individualized treatment regimens for relapsing MS by incorporating recent information on new and emerging therapies that target B lymphocytes, Compare available and novel imaging approaches for monitoring disease status and facilitating treatment decisions in relapsing MS.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education